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Abstract
The aim of the English NHS Diabetic Eye Screening Programme (DESP) is to reduce the risk of sight loss amongst people 
with diabetes by the prompt identification and effective treatment if necessary of sight-threatening diabetic retinopathy, 
at the appropriate stage during the disease process, with a long-term aim of preventing blindness in people with diabetes.
For the year 2009–2010, diabetic retinopathy (DR) was no longer the leading cause of blindness in the working age group. 
There have been further reductions in DR certifications for WHO severe vision impairment and blindness from 1,334 (5.5% 
of all certifications) in 2009/2010 to 840 (3.5% of all certifications) in 2018/2019. NHS DESP is a major contributor to 
this further reduction, but one must also take into account improvements in glycaemic and blood pressure control, timely 
laser treatment and vitrectomy surgery, improved monitoring techniques for glycaemic control, and vascular endothelial 
growth factor inhibitor injections for control of diabetic macular oedema. The latter have had a particular impact since first 
introduced in the UK in 2013.
Current plans for NHS DESP include extension of screening intervals in low-risk groups and the introduction of optical 
coherence tomography as a second line of screening for those with screen positive maculopathy with two dimensional mark-
ers. Future challenges include the introduction of automated analysis for grading and new camera technologies.
Keywords Screening · Diabetic retinopathy · Vision impairment · Blindness
The English NHS Diabetic Eye Screening 
Programme
The NHS Diabetic Eye Screening Programme in England 
commenced in 2003 and achieved high population coverage 
and uptake by 2008. In 2017–2018, 2.70 million people with 
diabetes were offered screening [1] and 2.23 million screened 
(82.7%). This resulted in 8,782 urgent referrals and 54,893 
routine referrals to ophthalmology departments. The screen-
ing method is two 45-degree field mydriatic digital photogra-
phy per eye with screening and grading being undertaken by 
trained technicians or optometrists as previously described [2].
In 2014, Liew [3] reported that, from an analysis of blind-
ness certifications in the year 2009–2010, for the first time in 
at least five decades diabetic retinopathy/maculopathy was 
no longer the leading cause of certifiable blindness among 
working age adults in England. In 2013, an eye health indi-
cator was incorporated into the Public Health Outcomes 
Framework [4] in England which resulted in ongoing annual 
reports being produced from certificates of vision impair-
ment (CVIs) that are gathered and collated at Moorfields Eye 
Hospital, which have resulted in three further publications 
about blindness certifications in the UK [5–7]. In England, 
despite an overall increase in the numbers of certifications, 
the numbers that have diabetic eye disease as the main cause 
have shown a reduction from 1334 (5.5% of all certifications) 
in 2009/10 to 840 (3.5% of all certifications) in 2018/2019 
(Table 1 and Fig. 1). The reduction has been principally in 
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the age group 35 years and older from 1207 to 758, with an 
average of 51 per year in those aged 18–34 years which has 
shown little change over the same period.
Worldwide blindness due to diabetic 
retinopathy
Table 2 compares the different definitions that have been 
used in reporting blindness so that comparisons between 
studies can be more easily understood.
A 2020 publication [8] by a Vision Loss Expert Group 
of Collaborators reported that although diabetic retinopathy 
accounted for 0·86 million cases [0·59–1·23] of blindness in 
those aged 50 years and older in 2020, it was the smallest 
contributor to blindness in 2020 compared with under cor-
rected refractive error, cataract, age-related macular degen-
eration, and glaucoma. However, it was the only cause of 
blindness that showed a global increase in age standardised 
prevalence between 1990 and 2020, which was of particular 
concern in younger, economically active age groups.
Diabetes in Western Europe
In the Diabetes Atlas 2019 report [9], the age-adjusted com-
parative prevalence of diabetes in Western Europe was 6.3% 
expecting to rise to 7.3% in 2030.
In the UK, the National Diabetes Audit [10] from 
2018–2019 recorded 7% of the population (3,537,385 peo-
ple) with diabetes.
A recent publication [11] describing the implementa-
tion and 15-year follow-up of a population-based screen-
ing program in Andalusia in Southern Spain, which has a 
population of 8.4 million, reported that the prevalence of 
diabetes in Andalusia is higher (15.3%) than in the rest of 
Spain (12.5%).
Blindness in Western Europe
In 2002, Kocur [12] reported that in people of working age 
in Europe, diabetic retinopathy was the most frequently 
reported causes of serious visual loss.
In 2012, Sivaprasad reported that minority ethnic com-
munities with type 2 diabetes in the UK, in particular those 
of African/Afro-Caribbean’s and South Asian origin, are 
more prone to visual impairment including sight-threaten-
ing retinopathy and maculopathy [13], compared to white 
Europeans.
In 2018, Bourne [14] reported that the estimated num-
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was 1.16 (0.60–1.83) million and that 3.30 (0.47–7.60) 
% caused by DR suggesting that 38,280 people may be 
registered blind in Western Europe due to DR.
The 2020 publication [8] by a Vision Loss Expert 
Group of Collaborators report commented that there are 
surprisingly few data from high-income regions—only 
19 studies included in the review reported cause-specific 
vision impairment in a high-income location, and all but 
three of these took place more than a decade ago.
Comparisons between studies that have been reported 
are made more difficult by the following:
Populations studied
a) Some studies are based on patients attending hospital 
clinics, and others are more population based.
b) Other studies report on the numbers per 100,000 in 
the general population rather than on the numbers per 
100,000 with diabetes.
Fig. 1  Percentage of new certi-
fications of the combination of 
WHO severe vision impairment 
and blindness due to diabetic 










2011/12 2012/13 2013/14 2014/15 2015/16 2016/17 2017/18 2018/19
% of total 
cerficaons
Year
Diabec Eye Disease Main + Contributory Cause Diabec Eye Disease Main Cause
Table 2  Definitions of blindness and vision impairment
Registration Category Visual acuity in the better eye
Worse than Equal to or better than
WHO criteria 6 m 20 Feet LogMAR 6 m 20 Feet LogMAR
Mild vision impairment 6/12 20/40 0.3 6/18 20/60 0.48
Moderate vision impairment 6/18 20/60 0.48 6/60 20/200 1.0
Legal blindness USA and many Western 
European countries Sight impaired 
Certification UK
WHO Severe vision impairment 6/60 20/200 1.0 3/60 20/400 1.3
Seriously sight impaired/legal blindness 
certification UK
WHO blindness 3/60 20/400 1.3
WHO Near vision impairment N6 or M 
0.8 at 
40 cm
Categorisation by Central Visual Field: Degrees
WHO Severe vision impairment 20
WHO blindness 10
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Incomplete reporting of data
In the UK, retrospective reviews of WHO severe vision 
impairment and blindness registrations have been made in 
several subpopulations and at a national level like in this 
article. Those registers that are held locally are more likely 
to be complete, but registration for an individual patient is 
still voluntary. There are more financial benefits for an indi-
vidual who is registered WHO blind (severely sight impaired 
UK) than one who is registered as WHO severely visually 
impaired (sight impaired UK) which would suggest that the 
former may have more complete numbers than the latter. 
The national figures rely on data being sent to the certi-
fications centre at Moorfields Eye Hospital which is very 
complete from some areas of the country, but there will be 
under reporting from other areas.
Mortality of those with blindness due to DR
Only patients who were alive at follow-up may have been 
included in some studies even though it has been shown in 
the past that the mortality of those who have severe visual 
impairment or blindness is higher than those without [15].
Patient consent
In studies requiring patient consent, those who have lost 
vision may decline to participate [15].
Inclusion of blindness from other causes 
than diabetic retinopathy
Some studies [16, 17] included blindness from other causes 
than diabetic retinopathy in the population with diabetes. In 
2003, the point prevalence [16] of legal blindness in Arhus 
County, Denmark, found was 0.6% for type 1 and 1.5% 
for type 2 diabetes patients. However, in type 1 diabetes 
patients, 66.2% of blind eyes were due to proliferative DR 
(PDR) and in type 2 diabetes, 21.9% was due to age-related 
macular degeneration, 18.5% diabetic maculopathy and 18% 
PDR.
Summary of studies from Western Europe 
in populations with diabetes
Tables 3 and 4 include studies that could be converted to 
WHO definitions of severe visual impairment and blind-
ness due to diabetic retinopathy and to numbers per 100,000 
population with diabetes. Table 3 commences in 1993–1996 
with two hospital-based studies showing reductions in blind-
ness rates in Sweden [18, 19], followed by further reports 
reductions in blindness from Sweden [20] and Iceland [21] 
that they attributed to early detection of sight-threatening 
diabetic retinopathy by screening programmes. Studies 
by Nicolucci [22] in Italy, Cormack [23] in Scotland, and 
Kumar [24] in Leeds, England, provide background data of 
blindness levels in these areas at that time. In 2001, Traut-
ner [25] reported reductions in blindness between 1990 and 
1998 in people with diabetes in the area of Wurttemberg-
Hohenzollern, Germany. In 2003 Arun [26] reported regis-
tration data from Newcastle, which was an area that had pio-
neered screening in the UK, and reported [27] figures from 
the working age population in 2009. Grausland [15] reported 
the 25-year cumulative crude incidence of blindness in type 
1 diabetes was 7.5% (men, 8.0%; women, 6.8%; P = 0.61), 
corresponding to a mortality-adjusted cumulative incidence 
of blindness of 9.5% (95% CI, 7.1%–12.0%) and an overall 
incidence rate of blindness of 4.11 per 1000 person-years 
(95% CI, 3.03–5.59 per 1000 person-years). Further reports 
in Tables 3 and 4 include reductions in blindness related to 
diabetic retinopathy in Poland [28], Cambridge UK [29], 
Scotland [30], Ireland [31], Wales [32], Southern Germany 
[33], and Gloucestershire UK [34]. A report from Hungary 
[35] assessed WHO severe visual impairment and blindness 
levels using ‘Rapid Assessments of Avoidable Blindness’ 
(RAAB) in 105 clusters.
An Italian publication in 1994 reported [36] that diabetic 
retinopathy was the second most common cause of blindness 
(13.1%) in the province of Turin between 1967 and 1991 and 
the commonest cause of blindness in the age group 50–70. 
A further study [37] published in 2010 reported that diabetic 
retinopathy was the still the second most common cause of 
blindness (15%) in the province of Viterbo in 2002–2003.
In Finland, a National Register of Visual Impairment (VI) 
was established in 1982. A 2016 publication [38] reported 
on 4080 patients whose primary cause for vision impair-
ment (VI) was DR using three 10-year cohorts (1982–1990, 
1991–2000, 2001–2010). A significant change had occurred 
over the 10-year periods particularly in those diagnosed 
with proliferative diabetic retinopathy, characterised by an 
increasing age at the time of VI notification 39, 62, and 59, 
decreasing severity of VI with a lower proportion blind 42%, 
22%, and 15% and higher age at death 54, 73, and 72 years. 
Although the register does not collect data on type of dia-
betes, despite the fact that there had been an increase over 
this time of insulin-treated T2DM, it is believed that there 
has been a genuine change in characteristics of those with 
T1DM. This is further supported by the observation that 
the proportion of VI related to DR in persons of working 
age had decreased from 15% in 1990 to 10% in 2010. The 
article also comments on an unchanged small number of 
blind patients with a median age of 29–31 yrs, similar to the 
findings in the UK of unchanged number of registrations 
reported in the 18–34 yrs age group, reflecting the problems 
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in control of diabetes in some patients with diabetes in their 
late teens and twenties.
Contributions to reductions of blindness 
in Western Europe
Landmark clinical trials and studies have shown the 
importance of the following factors in the development of 
sight-threatening diabetic retinopathy and diabetic macular 
oedema:
1. Glycaemic control [39–42]
2. Control of blood pressure [39, 40, 43, 44]
In addition, the following have reduced the incidence 
and prevalence of blindness:
3. Timely laser treatment for proliferative DR [45]
4. Timely laser treatment for clinically significant mac-
ular oedema [46]
5. Vitrectomy surgery [29]
6. Screening.
Early reports that screening and screening compliance 
were major contributors in preventing and/or reducing DR 
blindness came from Iceland [21], 47. This was reported 
on a larger scale when, 6 years after the introduction of the 
English Screening Programme, Liew [3] reported that, in 
the year 2009–2010, diabetic retinopathy/maculopathy was 
no longer the leading cause of certifiable blindness among 
working age adults in England. The 2019 World Report on 
Vision [48] produced by the World Health Organisation 
concluded that ‘this provides compelling evidence that 
systematic diabetic retinopathy screening, coupled with 
timely treatment of sight-threatening disease, can reduce 
vision impairment and blindness’.
Since 2010, further contributions to reductions in blind-
ness are:
7. Vascular endothelial growth factor (VEGF) Inhibitor 
injections for diabetic macular oedema
VEGF inhibitor injections for diabetic macular oedema 
(DME) were available in England following approval 
by the National Institute of Health and Care Excellence 
(NICE)[49, 50] in 2013–2015, and in some other parts of 
Europe earlier than 2013 after they gained European Regu-
latory approval for diabetic macular oedema in 2010[51] 
and 2014[52]. A modelling study [53] in Japan calculated 
from 570,000 DME patients was included in a model over 
5 years. Increased utilization of anti-VEGF agents resulted 
in 6,659 fewer cases of severe visual impairment (SVI; 
26–35 ETDRS letters) or blindness (0–25 ETDRS letters) 
compared with the current care approach.
8. Intravitreal steroid treatments for DME that were 
available in England following approval [54, 55] by 
the National Institute of Health and Care Excellence in 
2013–15.
9. More recent treatments to improve glycaemic control 
in type 1 [56] and type 2 diabetes [57]
10. Improved methods of monitoring [58] glycaemic con-
trol.
Future developments and challenges 
for the English NHS Diabetic Eye Screening 
Programme
The current plans for the English NHS Diabetic Eye Screen-
ing Programme are.
1. Extension of screening intervals for low-risk groups 
based on their previous two screening results [59].
This is because we do not have easy access to other risk 
factor data and the most significant risk factor is what if 
any retinopathy was present on the most recent screening 
photographs [60].
2. The introduction of optical coherence tomography 
(OCT) in second-line digital surveillance clinics for those 
with screen positive diabetic maculopathy [61].
Our future challenges are:
1. The introduction of automated analysis for grading.
My own view is that we are most likely to introduce this 
at the DR/No DR level as they do in Scotland [62] to remove 
normal images from the grading queue in order to reduce the 
workload for graders in the English Screening Programme.
2. The assessment and introduction of new camera tech-
nologies for screening
If the new scanning confocal ophthalmoscopes are as 
good as is claimed [63] in the non-mydriatic format, there 
would be many advantages in introducing staged mydria-
sis into the English Screening Programme. At the present 
time, Scotland has to dilate 30% of their screening popula-
tion [64] with higher numbers in older people with diabetes 
(62% ≥ 85yrs and 50% 75–84 yrs).
If we could find a camera that successfully photographs 
the area covered by the two 45 degree fields currently used 
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by the English NHS DESP, the ungradable image rate with-
out drops was < 10%, and this was shown to be cost-effective 
(i.e., was not prohibitively expensive), this would be very 
attractive to the programme. There are many factors that 
influence young people with diabetes in resisting attendance 
at screening, but removing the need for dilating eye drops 
may be one that could help attendance in this age group.
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